В США одобрен новый препарат для лечения атопического дерматита
Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило моноклональные антитела дупилумаб (dupilumab) в форме подкожных инъекций для атопического дерматита у взрослых умеренной и тяжелой степени. Соответствующий документ был принят 28 марта 2017 года.
Препарат предназначен для пациентов, у которых экзема не поддается лечению местными средствами или для их применения имеются противопоказания. Дупилумаб может использоваться как совместно с кортикостероидными препаратами, так и без них.
Активным компонентом нового препарата являются антитела к субъединице общей для двух провоспалительных интерлейкинов: ИЛ-4 и ИЛ-13. В результате связывания с этими интерлейкинами дупилумаб ингибирует воспалительную реакцию, лежащую в основе атопического дерматита.
Исследования свойств нового препарата проводились в трех плацебо-контролируемых клинических испытаниях, в общей сложности охвативших 2119 взрослых участников с атопическим дерматитом от средней до тяжелой формы. Всем участвовавшим пациентам местные препараты (глюкокортикостероиды и ингибиторы кальциневрина) должным образом не помогали контролировать процесс.
В группе проходивших лечение дупилумабом (одна инъекция в неделю или в две недели) по сравнению с группой плацебо (одна инъекция в неделю) достигнут достоверно больший отклик, определяемый чистой или почти чистой кожей, а также снижением зуда после 16 недель лечения.
В клинических испытаниях была показана результативность дупилумаба при лечении других заболеваний со сходной этиологией — астмы и хронического полипозного синусита, однако одобрения FDA на расширенные показания к применению дупилумаба пока не получено.
Источники:
Medical news todayU. S. Food and Drug Administration
The New England Journal of Medicine
Drugs.com
6 апреля 2017
Фото: www.istockphoto.com/Tharakorn
Выпуск: №159, апрель 20172351 просмотров
Array ( [0] => Array ( [ID] => 16466 [~ID] => 16466 [NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor= [~NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor= [DATE_ACTIVE_FROM] => 01.09.2019 11:17:00 [~DATE_ACTIVE_FROM] => 01.09.2019 11:17:00 [IBLOCK_ID] => 12 [~IBLOCK_ID] => 12 [PREVIEW_PICTURE] => 8171 [~PREVIEW_PICTURE] => 8171 ) [PROPERTIES] => Array ( [SWF] => Array ( [ID] => 99 [TIMESTAMP_X] => 2018-08-19 19:34:17 [IBLOCK_ID] => 12 [NAME] => Ссылка во флеше (link1) [ACTIVE] => Y [SORT] => 500 [CODE] => SWF [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 50 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Ссылка во флеше (link1) [~DEFAULT_VALUE] => ) [LINK] => Array ( [ID] => 100 [TIMESTAMP_X] => 2018-08-19 19:34:17 [IBLOCK_ID] => 12 [NAME] => Ссылка (без протокола) [ACTIVE] => Y [SORT] => 500 [CODE] => LINK [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 50 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => 320465417 [VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0 [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0 [~DESCRIPTION] => [~NAME] => Ссылка (без протокола) [~DEFAULT_VALUE] => ) [WEBINARS] => Array ( [ID] => 102 [TIMESTAMP_X] => 2020-11-05 08:23:57 [IBLOCK_ID] => 12 [NAME] => Вебинары [ACTIVE] => Y [SORT] => 500 [CODE] => WEBINARS [DEFAULT_VALUE] => [PROPERTY_TYPE] => E [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 5 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => Y [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => EList [USER_TYPE_SETTINGS] => Array ( [size] => 20 [width] => 0 [group] => Y [multiple] => Y ) [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Вебинары [~DEFAULT_VALUE] => ) [TYPES] => Array ( [ID] => 103 [TIMESTAMP_X] => 2018-08-20 03:08:52 [IBLOCK_ID] => 12 [NAME] => Где показывать [ACTIVE] => Y [SORT] => 500 [CODE] => TYPES [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 20 [COL_COUNT] => 30 [LIST_TYPE] => C [MULTIPLE] => Y [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => Y [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => Array ( [0] => 320482201 ) [VALUE] => Array ( [0] => Страница статьи (273px) ) [DESCRIPTION] => Array ( [0] => ) [VALUE_ENUM] => Array ( [0] => Страница статьи (273px) ) [VALUE_XML_ID] => Array ( [0] => ade3837e8e0b9a67adab1fec2bc57639 ) [VALUE_SORT] => Array ( [0] => 500 ) [VALUE_ENUM_ID] => Array ( [0] => 458 ) [~VALUE] => Array ( [0] => Страница статьи (273px) ) [~DESCRIPTION] => Array ( [0] => ) [~NAME] => Где показывать [~DEFAULT_VALUE] => ) [RUBRICS] => Array ( [ID] => 104 [TIMESTAMP_X] => 2018-08-20 03:09:12 [IBLOCK_ID] => 12 [NAME] => Рубрики [ACTIVE] => Y [SORT] => 500 [CODE] => RUBRICS [DEFAULT_VALUE] => [PROPERTY_TYPE] => G [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 20 [TMP_ID] => [LINK_IBLOCK_ID] => 2 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => Y [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Рубрики [~DEFAULT_VALUE] => ) [VIEWS] => Array ( [ID] => 105 [TIMESTAMP_X] => 2018-08-19 23:38:24 [IBLOCK_ID] => 12 [NAME] => Показы [ACTIVE] => Y [SORT] => 500 [CODE] => VIEWS [DEFAULT_VALUE] => [PROPERTY_TYPE] => N [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Показы [~DEFAULT_VALUE] => ) [CLICKS] => Array ( [ID] => 106 [TIMESTAMP_X] => 2018-08-19 23:38:24 [IBLOCK_ID] => 12 [NAME] => Клики [ACTIVE] => Y [SORT] => 500 [CODE] => CLICKS [DEFAULT_VALUE] => [PROPERTY_TYPE] => N [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Клики [~DEFAULT_VALUE] => ) [ARTICLE] => Array ( [ID] => 116 [TIMESTAMP_X] => 2019-05-17 13:18:54 [IBLOCK_ID] => 12 [NAME] => Статьи [ACTIVE] => Y [SORT] => 500 [CODE] => ARTICLE [DEFAULT_VALUE] => [PROPERTY_TYPE] => E [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 2 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => EList [USER_TYPE_SETTINGS] => Array ( [size] => 20 [width] => 0 [group] => N [multiple] => Y ) [HINT] => [PROPERTY_VALUE_ID] => Array ( [0] => 320482202 ) [VALUE] => Array ( [0] => 32724 ) [DESCRIPTION] => Array ( [0] => ) [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => Array ( [0] => 32724 ) [~DESCRIPTION] => Array ( [0] => ) [~NAME] => Статьи [~DEFAULT_VALUE] => ) [CRIB] => Array ( [ID] => 117 [TIMESTAMP_X] => 2019-05-30 07:53:16 [IBLOCK_ID] => 12 [NAME] => Шпаргалки [ACTIVE] => Y [SORT] => 500 [CODE] => CRIB [DEFAULT_VALUE] => [PROPERTY_TYPE] => E [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => [FILE_TYPE] => [MULTIPLE_CNT] => 5 [TMP_ID] => [LINK_IBLOCK_ID] => 3 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => EList [USER_TYPE_SETTINGS] => Array ( [size] => 20 [width] => 0 [group] => N [multiple] => N ) [HINT] => [PROPERTY_VALUE_ID] => [VALUE] => [DESCRIPTION] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [~VALUE] => [~DESCRIPTION] => [~NAME] => Шпаргалки [~DEFAULT_VALUE] => ) ) [1] => Array ( [ID] => 15705 [~ID] => 15705 [NAME] => Стелланин апрель [~NAME] => Стелланин апрель [DATE_ACTIVE_FROM] => 01.04.2019 13:37:00 [~DATE_ACTIVE_FROM] => 01.04.2019 13:37:00 [IBLOCK_ID] => 12 [~IBLOCK_ID] => 12 [PREVIEW_PICTURE] => 7449 [~PREVIEW_PICTURE] => 7449 ) [2] => Array ( [ID] => 32741 [~ID] => 32741 [NAME] => Береш Май Обзор писем РЗН [~NAME] => Береш Май Обзор писем РЗН [DATE_ACTIVE_FROM] => 28.05.2020 08:53:00 [~DATE_ACTIVE_FROM] => 28.05.2020 08:53:00 [IBLOCK_ID] => 12 [~IBLOCK_ID] => 12 [PREVIEW_PICTURE] => 10191 [~PREVIEW_PICTURE] => 10191 ) )
2351 просмотров
Поделиться ссылкой с друзьями ВКонтакте Одноклассники
Нашли ошибку? Выделите текст и нажмите Ctrl+Enter.
зарегистрированным пользователям